These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Acute dystonic reaction to lithium and risperidone. Durrenberger S; de Leon J J Neuropsychiatry Clin Neurosci; 1999; 11(4):518-9. PubMed ID: 10570771 [No Abstract] [Full Text] [Related]
43. What happened to patients with behavioural and psychological symptoms of dementia (BPSD) after the Committee on Safety in Medicines (CSM) guidelines? Raju J; Sikdar S; Krishna T Int J Geriatr Psychiatry; 2005 Sep; 20(9):898-9. PubMed ID: 16116573 [No Abstract] [Full Text] [Related]
44. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability. Thyssen A; Remmerie B; D'Hoore P; Kushner S; Mannaert E Clin Ther; 2007 Feb; 29(2):290-304. PubMed ID: 17472821 [TBL] [Abstract][Full Text] [Related]
46. Cerebro- and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications. Jerrell JM; McIntyre RS Hum Psychopharmacol; 2007 Aug; 22(6):361-4. PubMed ID: 17562519 [TBL] [Abstract][Full Text] [Related]
47. Amisulpride versus risperidone treatment for behavioral and psychological symptoms in patients with dementia of the Alzheimer type: a randomized, open, prospective study. Lim HK; Pae CU; Lee C; Lee CU Neuropsychobiology; 2006; 54(4):247-51. PubMed ID: 17356308 [TBL] [Abstract][Full Text] [Related]
48. Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia. Suh GH; Greenspan AJ; Choi SK Int J Geriatr Psychiatry; 2006 Jul; 21(7):654-60. PubMed ID: 16821257 [TBL] [Abstract][Full Text] [Related]
49. Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia. Marinis TD; Saleem PT; Glue P; Arnoldussen WJ; Teijeiro R; Lex A; Latif MA; Medori R Pharmacopsychiatry; 2007 Nov; 40(6):257-63. PubMed ID: 18030649 [TBL] [Abstract][Full Text] [Related]
50. Risperidone-induced sexual dysfunction in a prepubertal child - a case report. Wadoo O; Chalhoub N J Psychopharmacol; 2009 Aug; 23(6):727-8. PubMed ID: 18562402 [TBL] [Abstract][Full Text] [Related]
52. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies. Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596 [TBL] [Abstract][Full Text] [Related]
53. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Melkersson KI Hum Psychopharmacol; 2006 Dec; 21(8):529-32. PubMed ID: 17094165 [TBL] [Abstract][Full Text] [Related]
54. CSM warning on atypical psychotics and stroke may be detrimental for dementia. Mowat D; Fowlie D; MacEwan T BMJ; 2004 May; 328(7450):1262. PubMed ID: 15155521 [No Abstract] [Full Text] [Related]
55. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine]. Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790 [TBL] [Abstract][Full Text] [Related]